布地格福吸入气雾剂联合茶碱缓释片治疗COPD的效果

Therapeutic effect of budesonide,glycopyrronium bromide and formoterol fumarate inhalation aerosol combined with theophylline sustained-release tablets in the treatment of COPD

目的观察布地格福吸入气雾剂联合茶碱缓释片治疗慢性阻塞性肺疾病(COPD)的效果。方法选取2021年4月—2023年4月兴仁市人民医院收治的94例COPD患者,按照随机数字表法分为茶碱组和联合用药组,各47例。在常规治疗基础上,茶碱组患者采用茶碱缓释片,联合用药组患者在茶碱组基础上采用布地格福吸入气雾剂。2组患者均连续治疗12周。比较2组临床疗效,治疗前后肺功能指标[用力肺活量(FVC)、第1秒用力呼气容积(FEV_(1))、呼气流量峰值(PEF)]、血气指标[动脉血氧分压(PaO_(2))、动脉血二氧化碳分压(PaCO_(2))]、实验室相关指标[血清基质金属蛋白酶-9(MMP-9)、降钙素原(PCT)、白介素-18(IL-18)、C反应蛋白(CRP)]及不良反应。结果联合用药组临床总有效率为95.74%,高于茶碱组的82.98%(χ^(2)=4.029,P=0.045)。治疗12周后,2组FVC、FEV_(1)、PEF及PaO_(2)高于治疗前,PaCO_(2)低于治疗前,且联合用药组升高/降低幅度大于茶碱组(P<0.01);联合用药组血清MMP-9、PCT、IL-18、CRP水平低于治疗前,且联合用药组低于茶碱组(P<0.01)。联合用药组不良反应总发生率(10.64%)与茶碱组(8.51%)比较,差异无统计学意义(P=1.000)。结论布地格福吸入气雾剂联合茶碱缓释片治疗COPD的疗效显著,可有效改善患者肺功能,调节血气指标,缓解炎性反应,促进疾病恢复,且安全性较高。

Objective To observe the therapeutic effect of budesonide,glycopyrronium bromide and formoterol fumarate inhalation aerosol combined with theophylline sustained-release tablets in the treatment of COPD.Methods A total of 94 patients with COPD admitted to Xingren City People′s Hospital from April 2021 to April 2023 were selected,and they were divided into the theophylline group and the combination group by random number table method,47 patients in each group.All patients were given basic treatment,and the theophylline group was treated with theophylline sustained-release tablets,and the combination group was treated with budesonide,glycopyrronium bromide and formoterol fumarate inhalation aerosol,both groups were treated with 12 weeks.Clinical effect,pulmonary function indexes(FVC,FEV_(1),PEF),blood gas analysis indicators(PaO_(2),PaCO_(2)),laboratory related indexes(MMP-9,PCT,IL-18,CRP)before and after treatment,incidence of adverse reactions were compared between the two groups.Results Total effective rate of the combination group was 95.74%,which was higher than 82.98%in the theophylline group(χ^(2)=4.029,P=0.045).After treatment of 12 weeks,FVC,FEV_(1),PEF and PaO_(2) of the two groups were higher than those before treatment,PaCO_(2) was lower than that before treatment,and the indexes in the combination group were higher/lower than those in the theophylline group(P<0.01);Serum levels of MMP-9,PCT,IL-18,CRP of the two groups were lower than those before treatment,and the combination group were lower than those in the theophylline group(P<0.01).There was no significnat difference in the incidence of adverse reactions between the combination group(10.64%)and the theophylline group(8.51%)(P=1.000).Conclusion Budesonide,glycopyrronium bromide and formoterol fumarate inhalation aerosol combined with theophylline sustained-release tablets have an exactly clinical effect in the treatment of COPD,it can effectively improve patients′pulmonary function,regulate blood gas indicators,relieve inflammatory reaction and promote the disease recovery,and with higher safety.